MTOR and neoplasm: MiR-148a and miR-361-5p activate the PI3K/AKT/mTOR pathway, inhibiting their targets RAB12 and FOXM1. The overexpression of miR-148a and miR-361-5p increased the sensitivity of tumor cells to chemotherapy drugs [47,53].